- Pharmaceutical giant Novo Nordisk has reduced the direct-to-consumer cash price for its popular drugs Wegovy and Ozempic from $499 to $349 per month.
- New cash-paying patients can take advantage of a temporary introductory offer, accessing the lowest doses for $199 per month for the first two months.
- The price cuts follow a recent agreement between the Trump administration, Novo Nordisk, and rival Eli Lilly to improve the affordability of GLP-1 medications.
- The move comes as the government prepares to launch its own direct-to-consumer platform, TrumpRx, to offer discounted drugs.
Pharmaceutical company Novo Nordisk announced on Monday a significant price reduction for its blockbuster weight-loss drug Wegovy and its diabetes counterpart, Ozempic. The company has lowered the monthly cost for existing cash-paying patients to $349, a notable drop from the previous price of $499.
A Push for Greater Affordability
The decision comes just days after President Donald Trump announced deals with Novo Nordisk and its main competitor, Eli Lilly, aimed at making popular GLP-1 drugs more accessible and affordable for Americans. These agreements are part of a broader administration effort to lower healthcare costs, which includes the upcoming launch of a government direct-to-consumer website called TrumpRx in January.
“Our new savings offers provide immediate impact, bringing forward greater cost savings for those who are currently without coverage or choose to self-pay,” said Dave Moore, Novo Nordisk’s head of U.S. operations, in a statement.
New Pricing and Introductory Offers
Beyond the standard price cut, Novo Nordisk is also rolling out a temporary introductory offer to attract new users. New cash-paying patients can now access the two lowest doses of Wegovy and Ozempic for just $199 per month for their first two months of treatment. Following this initial period, the price will adjust to the new standard rate of $349 per month. This introductory deal is set to expire on March 31.
However, the company noted that the cash-pay price for the highest dose of Ozempic will remain at $499 per month.
Industry-Wide Efforts to Lower Costs
This move is part of a larger trend of pharmaceutical companies responding to pressure to lower the costs of these in-demand treatments. Following its own deal with the administration, Eli Lilly announced it would lower prices for its weight-loss drug, Zepbound, on its direct-to-consumer platform, LillyDirect. The lowest dose of Zepbound will be available for $299 per month.
The Trump administration has stated that starting doses for drugs like Wegovy and Zepbound will be available for $350 per month on the new TrumpRx platform, with prices expected to decrease to $245 over two years.
How to Access the Discounts
Patients looking to take advantage of Novo Nordisk’s new pricing can do so through several channels. The offers are available on the official Wegovy and Ozempic websites, through the company’s own pharmacy service NovoCare, and via participating partners. These partners include major retailers and telehealth providers such as Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed.